DNA was extracted from the tumor tissue ; mutation screening in the PIK3CA gene ( exons 9 and 20 ) and the KRAS gene ( exons 2 and 3 ) was first carried out using Sanger direct sequencing , and then completed by next-generation sequencing for PIK3CA .